KNSA Strangle Strategy
KNSA (Kiniksa Pharmaceuticals, Ltd.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.
KNSA (Kiniksa Pharmaceuticals, Ltd.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $4.44B, a trailing P/E of 61.92, a beta of 0.17 versus the broader market, a 52-week range of 24.85-59.87, average daily share volume of 741K, a public-listing history dating back to 2018, approximately 315 full-time employees. These structural characteristics shape how KNSA stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.17 indicates KNSA has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure. The trailing P/E of 61.92 is on the rich side, which tends to correlate with higher earnings-window IV expansion as the market debates whether forward growth supports the multiple.
What is a strangle on KNSA?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current KNSA snapshot
As of May 15, 2026, spot at $56.59, ATM IV 46.00%, IV rank 10.09%, expected move 13.19%. The strangle on KNSA below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this strangle structure on KNSA specifically: KNSA IV at 46.00% is on the cheap side of its 1-year range, which favors premium-buying structures like a KNSA strangle, with a market-implied 1-standard-deviation move of approximately 13.19% (roughly $7.46 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated KNSA expiries trade a higher absolute premium for lower per-day decay. Position sizing on KNSA should anchor to the underlying notional of $56.59 per share and to the trader's directional view on KNSA stock.
KNSA strangle setup
The KNSA strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With KNSA near $56.59, the first option leg uses a $59.42 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed KNSA chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 KNSA shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $59.42 | N/A |
| Buy 1 | Put | $53.76 | N/A |
KNSA strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
KNSA strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on KNSA. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on KNSA
Strangles on KNSA are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the KNSA chain.
KNSA thesis for this strangle
The market-implied 1-standard-deviation range for KNSA extends from approximately $49.13 on the downside to $64.05 on the upside. A KNSA long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current KNSA IV rank near 10.09% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on KNSA at 46.00%. As a Healthcare name, KNSA options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to KNSA-specific events.
KNSA strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. KNSA positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move KNSA alongside the broader basket even when KNSA-specific fundamentals are unchanged. Always rebuild the position from current KNSA chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on KNSA?
- A strangle on KNSA is the strangle strategy applied to KNSA (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With KNSA stock trading near $56.59, the strikes shown on this page are snapped to the nearest listed KNSA chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are KNSA strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the KNSA strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 46.00%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a KNSA strangle?
- The breakeven for the KNSA strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current KNSA market-implied 1-standard-deviation expected move is approximately 13.19%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on KNSA?
- Strangles on KNSA are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the KNSA chain.
- How does current KNSA implied volatility affect this strangle?
- KNSA ATM IV is at 46.00% with IV rank near 10.09%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.